Biogen (BIIB) Says it Plans Regulatory Filing for Aducanumab in Alzheimer's Disease After Consulting with FDA
Go back to Biogen (BIIB) Says it Plans Regulatory Filing for Aducanumab in Alzheimer's Disease After Consulting with FDA| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 197.19 -2.52 (1.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.71 | 52 Week High | $333.65 | |||
| Open | $198.88 | 52 Week Low | $223.02 | |||
| Day High | $201.22 | P/E | 25.25 | |||
| Day Low | $197.01 | EPS | $7.81 | |||
| Volume | 1,146,494 | |||||
